Compare Citius Pharmaceuticals Inc (CTXR) vs CubeSmart (CUBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs CubeSmart — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while CubeSmart trades at $37.56 (market cap $8.45B). The key difference: CubeSmart is far larger — about 620.4× Citius Pharmaceuticals Inc's market cap, and CubeSmart pays a 5.65% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and CubeSmart for 89 Days on average.
| CTXR | CUBE | |
|---|---|---|
Market Cap | $13.62M | $8.45B |
Volume | 132,438 | 2,879,532 |
Sector | Health | Real Estate |
52-Week High | $1.82 | $42.50 |
52-Week Low | $0.48 | $35.36 |
Typical Hold Time | 16 Days | 89 Days |
Enterprise Value | $3.79M | $11.97B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
CUBE trades at $37.23, down 1.4% on the day, with a bearish technical signal and mixed earnings history including a Q2 2026 FFO miss. The company maintains strong profitability with a 29.41% net income margin and a 5.4% dividend yield, but faces headwinds from moderating revenue growth and high leverage.
The outlook is cautiously optimistic with a consensus price target of $44.00, though risks include elevated debt levels and sector oversupply. Upside hinges on operational improvements and a return to earnings growth in H2 2026 as guided.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About CubeSmart
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Read more on CUBE →
